"Countless hours of team review meetings"
As Invivyd scaled its clinical operations and approached a critical commercial launch, the company faced significant challenges in managing its clinical trial financials. At the time, R&D forecasting and period accruals posed a significant time and resource challenge. Each month, the team conducted countless hours of rigorous review meetings while heavily relying on Excel to consolidate numbers – exposing both risk and organizational inefficiency. Not only that, but these hours of data prep and review failed to deliver data-driven insights to drive their business forward.
Contending with the speed of progress and needing to better manage the degree and frequency of changes in trials, Invivyd had to ensure that their accounting and reporting of ongoing trials was efficient and accurate.
It was imperative that they set up their accounting organization to meet the demands of current and future organization needs. Invivyd needed to quickly implement scalable processes and clinical finance best practices.
"Working with Auxilius has felt like a true partnership."
Invivyd was introduced to Auxilius as a solution to more efficiently deliver accurate accruals. In a little over a month, the Inviviyd team rolled out Auxilius for their phase 3 trial.
The implementation was focused on two objectives:
Looking ahead, the Invivyd finance team will continue to use Auxilius as a tool critical to the efficiency and effectiveness of their scaling business.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Invivyd is expanding their clinical footprint, advancing programs, and operating in the commercial market with an approved/launched product.
